Apricitabine Completed Phase 2 Trials for Human Immunodeficiency Virus (HIV) Infections Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Completed | Treatment | 2 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT00126880 | AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV | |
| NCT00367952 | A Long Term, Safety Study of Apricitabine in HIV-infected Subjects |